In a word, the multifunctional nanoparticle TPP‐LND@Lip developed by us could sensitize the radioimmunotherapy of lung cancer through metabolic reprogramming, which may be used as a possible alternative of PD‐L1 antibody in the clinical treatment of tumors. This evidence concerns the gene CD274 and lung carcinoma.